Not So Different: Goodwin Attorneys Discuss Updates to Biosimilars Litigation Guide

March 7, 2021

Key 2020-2021 updates to the Guide to Biosimilars litigation and Regulation in the US encompass antitrust litigation, preliminary injunctions, and a slowdown in litigation.

Before the battle for market share gets started, the courtroom is the OK Corral for biosimilar developers and reference product manufacturers, who duke it out over patents to determine how soon biosimilars can enter the marketplace. We spoke with Alexandra Valenti, JD, and Rob Cerwinski, JD, Goodwin partners and senior editors of the updated Guide to Biosimilars Litigation and Regulation in the US about some of the key developments.

To learn more about Valenti and Cerwinski's updated guide, click here.

To learn more about adalimumab patent disputes, click here.

To learn more about the future state for the adalimumab market, click here.

To take our quiz on adalimumab, click here.